FDAnews Device Daily Bulletin

ISOTECHNIKA SIGNS OPTION AGREEMENT FOR TOPICAL DELIVERY TECHNOLOGY OF ISA247

April 26, 2006
A A

Isotechnika Inc. announced today that the Company has signed an option agreement with Cellgate Inc. of Redwood City, California. This agreement allows Isotechnika the option to obtain an exclusive license to develop and commercialize conjugates consisting of Cellgate's patented transporter technology for the topical delivery of ISA247 in patients suffering from mild to moderate psoriasis.
Isotechnika